BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 31856595)

  • 1. m
    Chen Y; Zhou C; Sun Y; He X; Xue D
    Epigenomics; 2020 Jan; 12(2):87-99. PubMed ID: 31856595
    [No Abstract]   [Full Text] [Related]  

  • 2. Analysis and verification of
    Yang Z; Peng B; Pan Y; Gu Y
    Bioengineered; 2021 Dec; 12(2):9473-9483. PubMed ID: 34699322
    [No Abstract]   [Full Text] [Related]  

  • 3. Identification and validation of m6A-associated ferroptosis genes in renal clear cell carcinoma.
    Pang S; Zhao S; Dongye Y; Fan Y; Liu J
    Cell Biol Int; 2024 Jun; 48(6):777-794. PubMed ID: 38440906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The m
    Liu SY; Wu JJ; Chen ZH; Zou ML; Teng YY; Zhang KW; Li YY; Guo DY; Yuan FL
    Front Cell Dev Biol; 2021; 9():748703. PubMed ID: 34869335
    [No Abstract]   [Full Text] [Related]  

  • 5.
    Gu Y; Niu S; Wang Y; Duan L; Pan Y; Tong Z; Zhang X; Yang Z; Peng B; Wang X; Han X; Li Y; Cheng T; Liu Y; Shang L; Liu T; Yang X; Sun M; Jiang S; Zhang C; Zhang N; Ye Q; Gao S
    Cancer Res; 2021 Feb; 81(4):923-934. PubMed ID: 33293428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N
    von Hagen F; Gundert L; Strick A; Klümper N; Schmidt D; Kristiansen G; Tolkach Y; Toma M; Ritter M; Ellinger J
    Mol Carcinog; 2021 May; 60(5):354-362. PubMed ID: 33755994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a New Prognostic Risk Signature of Clear Cell Renal Cell Carcinoma Based on N
    Zhang Y; Yao Y; Qi X; Li J; Liu M; Che X; Xu Y; Wu G
    J Immunol Res; 2021; 2021():6617841. PubMed ID: 33628845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGR2-mediated regulation of m
    Ying Y; Ma X; Fang J; Chen S; Wang W; Li J; Xie H; Wu J; Xie B; Liu B; Wang X; Zheng X; Xie L
    Cell Death Dis; 2021 Jul; 12(8):750. PubMed ID: 34326314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. METTL14-mediated N
    Liu Z; Sun T; Piao C; Zhang Z; Kong C
    Cell Commun Signal; 2022 Mar; 20(1):36. PubMed ID: 35305660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma.
    Zhu D; Liu Y; Chen J; Wang Q; Li Y; Zhu Y; Feng J; Jiang J
    J Transl Med; 2022 Jul; 20(1):298. PubMed ID: 35794583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma.
    Zhang L; Luo X; Qiao S
    Br J Cancer; 2022 Jul; 127(1):30-42. PubMed ID: 35249103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. m
    Zhong J; Liu Z; Cai C; Duan X; Deng T; Zeng G
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33574053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m6A RNA methylation regulators correlate with malignant progression and have potential predictive values in clear cell renal cell carcinoma.
    Zhang QJ; Luan JC; Song LB; Cong R; Ji CJ; Zhou X; Xia JD; Song NH
    Exp Cell Res; 2020 Jul; 392(1):112015. PubMed ID: 32333907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New mechanistic insights of clear cell renal cell carcinoma from integrated miRNA and mRNA expression profiling studies.
    Qi Y; Wang L; Wang K; Peng Z; Ma Y; Zheng Z; Shang D; Xu W; Zheng J
    Biomed Pharmacother; 2019 Mar; 111():821-834. PubMed ID: 30616081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The analysis of N6-methyladenosine regulators impacting the immune infiltration in clear cell renal cell carcinoma.
    Li J; Cao J; Liang C; Deng R; Li P; Tian J
    Med Oncol; 2022 Jan; 39(4):41. PubMed ID: 35092501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine demethylase FTO suppresses clear cell renal cell carcinoma through a novel FTO-PGC-1α signalling axis.
    Zhuang C; Zhuang C; Luo X; Huang X; Yao L; Li J; Li Y; Xiong T; Ye J; Zhang F; Gui Y
    J Cell Mol Med; 2019 Mar; 23(3):2163-2173. PubMed ID: 30648791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of placenta specific 8 is associated with malignant progression and poor prognosis of clear cell renal cell carcinoma.
    Shi L; Xiao L; Heng B; Mo S; Chen W; Su Z
    Int Urol Nephrol; 2017 Jul; 49(7):1165-1176. PubMed ID: 28349447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the mechanism of clear cell renal cell carcinoma metastasis and key genes based on multi-tool joint analysis.
    Yang H; Li W; Lv Y; Fan Q; Mao X; Long T; Xie L; Dong C; Yang R; Zhang H
    Gene; 2019 Dec; 720():144103. PubMed ID: 31491435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased expression of BRAF-activated long non-coding RNA is associated with the proliferation of clear cell renal cell carcinoma.
    Xue S; Jiang SQ; Li QW; Wang S; Li J; Yang S; Zhang HM; Xu YF; Wang LS; Zheng JH
    BMC Urol; 2018 Sep; 18(1):79. PubMed ID: 30200918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Construction of circRNA-based ceRNA network to reveal the role of circRNAs in the progression and prognosis of metastatic clear cell renal cell carcinoma.
    Wei X; Dong Y; Chen X; Ren X; Li G; Wang Y; Wang Y; Zhang T; Wang S; Qin C; Song N
    Aging (Albany NY); 2020 Nov; 12(23):24184-24207. PubMed ID: 33223511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.